<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00702884</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-07121</org_study_id>
    <secondary_id>NCI-2011-03148</secondary_id>
    <nct_id>NCT00702884</nct_id>
  </id_info>
  <brief_title>Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer</brief_title>
  <official_title>A Mechanistic Radiographic and Biologic Phase 2 Single Agent Study of Sunitinib Malate in Relapsed/Refractory Esophageal and Gastroesophageal Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tony Bekaii-Saab</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes
      needed for cell growth and by blocking blood flow to the tumor.

      PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with
      relapsed or refractory esophageal or gastroesophageal junction cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine the progression-free survival rate (complete response, partial response,
           and stable disease as defined by RECIST criteria [Response Evaluation Criteria in solid
           Tumors]) at 24 weeks in patients with relapsed or refractory esophageal or
           gastroesophageal junction cancer treated with sunitinib malate.

      Secondary

        -  To explore the predictive role of a hybrid imaging protocol that combines PET/CT
           (Positron emission tomography) scan simultaneously with dynamic contrast-enhanced MRI.

        -  Correlate quantitative changes in mean vessel density, alterations in tumor cell
           proliferation, and apoptosis in tumor biopsy specimens with clinical outcome in these
           patients.

        -  To evaluate the objective response as defined by RECIST criteria, median overall
           survival, and median progression-free survival of these patients.

        -  To evaluate the toxicities of sunitinib malate in these patients.

      OUTLINE: Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every
      28 days in the absence of disease progression or unacceptable toxicity.

      Patients undergo blood and tumor tissue sample collection periodically for correlative
      laboratory studies. Tumor tissue samples are assessed by immunohistochemistry and TUNEL for
      detection and quantitation of mean vessel density, proliferating tumor cells, and apoptosis.
      Tumor tissue samples are also assessed by immunohistochemistry for MAPK levels. Blood samples
      are analyzed by ELISA for VEGF, PlGF, sVEGFR2, and sVEGFR3 levels. Patients also undergo
      PET/CT scan and dynamic contrast-enhanced MRI periodically for correlative studies.

      After completion of study treatment, patients are followed for at least 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 30, 2008</start_date>
  <completion_date type="Actual">December 30, 2013</completion_date>
  <primary_completion_date type="Actual">September 17, 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival Rate</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Complete response, partial response, and stable disease) as assessed by RECIST criteria at 24 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>up to 4 years</time_frame>
    <description>The Overall Response Rate (ORR) was assessed using Partial Response + Complete Response for patients. Response and progression was evaluated in this study using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival Time</measure>
    <time_frame>up to 4 years</time_frame>
    <description>The median overall survival time will be reported using the 95% confidence intervals for the parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Progression-free Survival Time</measure>
    <time_frame>up to 4 years</time_frame>
    <description>Progression free survival was measured as the time from start of treatment to the first measurement of tumor growth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Severity of Adverse Events</measure>
    <time_frame>up to 4 years</time_frame>
    <description>The National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 was utilized for adverse event reporting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Vessel Density</measure>
    <time_frame>up to 4 years</time_frame>
    <description>Quantitative assessment of proliferating tumor cells, and apoptosis, of the laboratory and radiographic correlates, the analyses will be purely explorative.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative Assessment of Proliferating Tumor Cells and Apoptosis</measure>
    <time_frame>up to 4 years</time_frame>
    <description>Biopsy sample taken from patients before and after treatment Apoptosis measures using the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay, which measures 3' nicked DNA. DNA is degraded in the early steps of apoptosis into low molecular weight (LMW) fragments and the production of single strand breaks in the high molecular weight DNA.Both of these features of apoptosis can be detected by labeling free 3'-OH termini with modified nucleotides, in our case this will be biotin-labeled dUTP. Terminal deoxynucleotidyl transferase (TdT) is an enzyme that labels blunt-ends of DNA breaks and can catalyze polymerization of nucleotides to free 3'-OH DNA ends in a template-independent manner. The newly incorporated nucleotides are detected by a secondary antibody, avidin-peroxidase. After substrate reaction, the stained cells can be detected and counted under a light microscope. Apoptotic cells will be fixed with formaldehyde which links LMW DNA</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Sunitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sunitinib 37.5 mg daily for a 4 week cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib malate</intervention_name>
    <description>Sunitinib 37.5 mg daily for a 4 week cycle</description>
    <arm_group_label>Sunitinib</arm_group_label>
    <other_name>Sutent</other_name>
    <other_name>SU011248 L-Malate salt</other_name>
    <other_name>SU010398</other_name>
    <other_name>PHA-290940AD</other_name>
    <other_name>SU011248</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed esophageal or gastroesophageal junction carcinoma that is not
             amenable to curative surgery or other curative therapy

               -  Advanced, relapsed or refractory disease

          -  Measurable disease, defined as at least one lesion that can be accurately measured in
             at least one dimension (longest diameter to be recorded) as ≥ 20 mm by conventional
             techniques or as ≥ 10 mm by spiral CT scan

          -  No known brain metastases

        PATIENT CHARACTERISTICS:

          -  ECOG (Eastern Cooperative Oncology Group) performance status 0-1

          -  Life expectancy &gt; 12 weeks

          -  WBC ≥ 3,000/μL

          -  Absolute neutrophil count ≥ 1,500/μL

          -  Platelet count ≥ 100,000/μL

          -  Serum calcium ≤ 12.0 mg/dL

          -  Total bilirubin normal

          -  AST (aspartate aminotransferase) and ALT (Alanine Aminotransferase) ≤ 2.5 times upper
             limit of normal

          -  Creatinine normal OR creatinine clearance ≥ 60 mL/min

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception prior to, during, and for 28 days
             after completion of study treatment

          -  No history of allergic reactions attributed to compounds of similar chemical or
             biologic composition to sunitinib malate

          -  No ongoing cardiac dysrhythmias ≥ grade 2, atrial fibrillation of any grade, or
             prolongation of the QTc (corrected QT interval) interval to &gt; 450 msec (for males) or
             &gt; 470 msec (for females)

          -  No hypertension that cannot be controlled by medications (i.e., systolic/diastolic
             blood pressure &gt; 150/100 mm Hg despite optimal medical therapy)

          -  No myocardial infarction, cardiac arrhythmia, stable/unstable angina, symptomatic
             congestive heart failure, or coronary/peripheral artery bypass graft or stenting
             within the past 12 months

          -  No cerebrovascular accident or transient ischemic attack within the past 12 months

          -  No pulmonary embolism within the past 12 months

          -  No condition that would impair the ability to swallow and retain sunitinib malate
             tablets (e.g., gastrointestinal tract disease resulting in an inability to take oral
             medication or a requirement for IV alimentation, prior surgical procedures affecting
             absorption, or active peptic ulcer disease)

          -  No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within
             the past 28 days

          -  No serious or nonhealing wound, ulcer, or bone fracture

          -  No pre-existing thyroid abnormality that cannot be maintained in the normal range with
             medication

          -  No concurrent uncontrolled illness including, but not limited to, ongoing or active
             infection or psychiatric illness/social situation that would limit compliance with
             study requirements

        PRIOR CONCURRENT THERAPY:

          -  Recovered from prior therapy

          -  At least 4 weeks since prior radiotherapy or major surgery

          -  At least 4 weeks since prior chemotherapy (6 weeks for mitomycin C, carmustine, or
             alkylating agents)

          -  No more than 6 prior courses of an alkylating agent

          -  No more than 450 mg/m² of prior doxorubicin hydrochloride or 900 mg/m² of prior
             epirubicin hydrochloride

          -  No more than 2 lines of prior therapy in the metastatic setting

          -  No prior anti-VEGF monoclonal antibodies, such as bevacizumab or aflibercept

          -  No prior tyrosine kinase inhibitors with similar targets (e.g., sorafenib tosylate or
             axitinib)

          -  No other concurrent investigational agents

          -  No concurrent therapeutic doses of coumarin-derivative anticoagulants, such as
             warfarin

               -  Warfarin at doses of ≤ 2 mg daily are allowed for prophylaxis of thrombosis

               -  Low molecular weight heparin allowed provided PT/INR (Prothrombin time and
                  international normalized ratio) is ≤ 1.5

          -  No concurrent combination antiretroviral therapy for HIV-positive patients

          -  No concurrent agents with proarrhythmic potential (e.g., terfenadine, quinidine,
             procainamide, disopyramide, sotalol, probucol, bepridil, haloperidol, risperidone,
             indapamide, and flecainide)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanios Bekaii-Saab, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>Jamesline</description>
  </link>
  <results_reference>
    <citation>Wu C, Mikhail S, Wei L, Timmers C, Tahiri S, Neal A, Walker J, El-Dika S, Blazer M, Rock J, Clark DJ, Yang X, Chen JL, Liu J, Knopp MV, Bekaii-Saab T. A phase II and pharmacodynamic study of sunitinib in relapsed/refractory oesophageal and gastro-oesophageal cancers. Br J Cancer. 2015 Jul 14;113(2):220-5. doi: 10.1038/bjc.2015.197. Epub 2015 Jul 7.</citation>
    <PMID>26151457</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2008</study_first_submitted>
  <study_first_submitted_qc>June 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2008</study_first_posted>
  <results_first_submitted>February 4, 2016</results_first_submitted>
  <results_first_submitted_qc>January 31, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 21, 2017</results_first_posted>
  <last_update_submitted>January 31, 2017</last_update_submitted>
  <last_update_submitted_qc>January 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>Tony Bekaii-Saab</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>recurrent esophageal cancer</keyword>
  <keyword>stage IIIA esophageal cancer</keyword>
  <keyword>stage IIIB esophageal cancer</keyword>
  <keyword>stage IIIC esophageal cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sunitinib</title>
          <description>Sunitinib 37.5 mg daily for a 4 week cycle
sunitinib malate: Sunitinib 37.5 mg daily for a 4 week cycle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sunitinib</title>
          <description>Sunitinib 37.5 mg daily for a 4 week cycle
sunitinib malate: Sunitinib 37.5 mg daily for a 4 week cycle</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="38" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival Rate</title>
        <description>Complete response, partial response, and stable disease) as assessed by RECIST criteria at 24 weeks</description>
        <time_frame>up to 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib</title>
            <description>Sunitinib 37.5 mg daily for a 4 week cycle
sunitinib malate: Sunitinib 37.5 mg daily for a 4 week cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival Rate</title>
          <description>Complete response, partial response, and stable disease) as assessed by RECIST criteria at 24 weeks</description>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="5.6" upper_limit="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate</title>
        <description>The Overall Response Rate (ORR) was assessed using Partial Response + Complete Response for patients. Response and progression was evaluated in this study using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0.</description>
        <time_frame>up to 4 years</time_frame>
        <population>Durable Complete Response= PR + SD &gt; 10 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib</title>
            <description>Sunitinib 37.5 mg daily for a 4 week cycle
sunitinib malate: Sunitinib 37.5 mg daily for a 4 week cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate</title>
          <description>The Overall Response Rate (ORR) was assessed using Partial Response + Complete Response for patients. Response and progression was evaluated in this study using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0.</description>
          <population>Durable Complete Response= PR + SD &gt; 10 weeks</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Overall Survival Time</title>
        <description>The median overall survival time will be reported using the 95% confidence intervals for the parameters.</description>
        <time_frame>up to 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib</title>
            <description>Sunitinib 37.5 mg daily for a 4 week cycle
sunitinib malate: Sunitinib 37.5 mg daily for a 4 week cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Median Overall Survival Time</title>
          <description>The median overall survival time will be reported using the 95% confidence intervals for the parameters.</description>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6" lower_limit="8.9" upper_limit="25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Progression-free Survival Time</title>
        <description>Progression free survival was measured as the time from start of treatment to the first measurement of tumor growth.</description>
        <time_frame>up to 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib</title>
            <description>Sunitinib 37.5 mg daily for a 4 week cycle
sunitinib malate: Sunitinib 37.5 mg daily for a 4 week cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Median Progression-free Survival Time</title>
          <description>Progression free survival was measured as the time from start of treatment to the first measurement of tumor growth.</description>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" lower_limit="5.6" upper_limit="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Severity of Adverse Events</title>
        <description>The National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 was utilized for adverse event reporting.</description>
        <time_frame>up to 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Grade 1 and 2 Adverse Events</title>
            <description>Grade 1=Mild; asymptomatic or mild symptoms
Grade 2=Moderate; minimal, local or noninvasive intervention indicated</description>
          </group>
          <group group_id="O2">
            <title>Grade 3 Adverse Events</title>
            <description>Grade 3=Severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated</description>
          </group>
          <group group_id="O3">
            <title>Grade 4 Adverse Events</title>
            <description>Grade 4=Life-threatening consequences; urgent intervention indicated</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Severity of Adverse Events</title>
          <description>The National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 was utilized for adverse event reporting.</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombocytopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Vessel Density</title>
        <description>Quantitative assessment of proliferating tumor cells, and apoptosis, of the laboratory and radiographic correlates, the analyses will be purely explorative.</description>
        <time_frame>up to 4 years</time_frame>
        <population>Insufficient tissue was available and the analysis for mean vessel density not performed</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib</title>
            <description>Sunitinib 37.5 mg daily for a 4 week cycle
sunitinib malate: Sunitinib 37.5 mg daily for a 4 week cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Vessel Density</title>
          <description>Quantitative assessment of proliferating tumor cells, and apoptosis, of the laboratory and radiographic correlates, the analyses will be purely explorative.</description>
          <population>Insufficient tissue was available and the analysis for mean vessel density not performed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quantitative Assessment of Proliferating Tumor Cells and Apoptosis</title>
        <description>Biopsy sample taken from patients before and after treatment Apoptosis measures using the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay, which measures 3’ nicked DNA. DNA is degraded in the early steps of apoptosis into low molecular weight (LMW) fragments and the production of single strand breaks in the high molecular weight DNA.Both of these features of apoptosis can be detected by labeling free 3’-OH termini with modified nucleotides, in our case this will be biotin-labeled dUTP. Terminal deoxynucleotidyl transferase (TdT) is an enzyme that labels blunt-ends of DNA breaks and can catalyze polymerization of nucleotides to free 3’-OH DNA ends in a template-independent manner. The newly incorporated nucleotides are detected by a secondary antibody, avidin-peroxidase. After substrate reaction, the stained cells can be detected and counted under a light microscope. Apoptotic cells will be fixed with formaldehyde which links LMW DNA</description>
        <time_frame>up to 4 years</time_frame>
        <population>Analysis for tumor cells not performed due to insufficient samples available</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib</title>
            <description>Sunitinib 37.5 mg daily for a 4 week cycle
sunitinib malate: Sunitinib 37.5 mg daily for a 4 week cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Quantitative Assessment of Proliferating Tumor Cells and Apoptosis</title>
          <description>Biopsy sample taken from patients before and after treatment Apoptosis measures using the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay, which measures 3’ nicked DNA. DNA is degraded in the early steps of apoptosis into low molecular weight (LMW) fragments and the production of single strand breaks in the high molecular weight DNA.Both of these features of apoptosis can be detected by labeling free 3’-OH termini with modified nucleotides, in our case this will be biotin-labeled dUTP. Terminal deoxynucleotidyl transferase (TdT) is an enzyme that labels blunt-ends of DNA breaks and can catalyze polymerization of nucleotides to free 3’-OH DNA ends in a template-independent manner. The newly incorporated nucleotides are detected by a secondary antibody, avidin-peroxidase. After substrate reaction, the stained cells can be detected and counted under a light microscope. Apoptotic cells will be fixed with formaldehyde which links LMW DNA</description>
          <population>Analysis for tumor cells not performed due to insufficient samples available</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Toxicities were graded according to NCI Common Toxicity Criteria version 3.0</desc>
      <group_list>
        <group group_id="E1">
          <title>Sunitinib</title>
          <description>Sunitinib 37.5 mg daily for a 4 week cycle
sunitinib malate: Sunitinib 37.5 mg daily for a 4 week cycle</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>GI Hemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>GI Hemorrhage</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tanios Bekaii-Saab</name_or_title>
      <organization>The Ohio State University Comprehensive Cancer Center</organization>
      <phone>614-293-6529</phone>
      <email>Tanios.Bekaii-Saab@osumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

